EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vistagen Therapeutics's enterprise value is $-21.53 Mil.
Vistagen Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.49 Mil. Therefore, Vistagen Therapeutics's EV-to-Revenue for today is -44.30.
The historical rank and industry rank for Vistagen Therapeutics's EV-to-Revenue or its related term are showing as below:
VTGN'
s EV-to-Revenue Range Over the Past 10 Years
Min: -119.76 Med: 7.95 Max: 387.74
Current: -44.3
During the past 13 years, the highest EV-to-Revenue of Vistagen Therapeutics was 387.74. The lowest was -119.76. And the median was 7.95.
VTGN's EV-to-Revenue is ranked better than 98.38% of 990
companies
in the Biotechnology industry
Industry Median: 7.805
vs VTGN: -44.30
Vistagen Therapeutics EV-to-Revenue Historical Data
The historical data trend for Vistagen Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vistagen Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Vistagen Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's EV-to-Revenue falls into.
Vistagen Therapeutics's current Enterprise Value is $-21.53 Mil.
Vistagen Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics's share price for today is $2.00.
Vistagen Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Vistagen Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your 